Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01982591 · ClinicalTrials.gov registry record
Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
A clinical trial, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- 115
- Enrollment target
NCT01982591 is a clinical trial that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 115 participants.
The verdict
NCT01982591 has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- 115 participants
- Enrollment target
Study Summary
This research trial studies heavy metal exposure in predicting peripheral neuropathy in patients with stage I-III breast cancer undergoing chemotherapy. Studying samples of blood and urine in the laboratory for heavy metal exposure from patients receiving chemotherapy may help doctors find out whether side effects from chemotherapy are related to heavy metal exposure.
Interventions
- OTHER laboratory biomarker analysis
- OTHER questionnaire administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2011-01-03 |
| Est. Completion | 2015-03-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01982591
The ClinicalTrials.gov registry entry for NCT01982591 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT01982591 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01982591 about?
NCT01982591 is a clinical study titled "Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy". This research trial studies heavy metal exposure in predicting peripheral neuropathy in patients with stage I-III breast cancer undergoing chemotherapy. Studying samples of blood and urine in the laboratory for heavy metal exposure from patients receiving chemotherapy may help doctors find out wheth...
What is the current status of trial NCT01982591?
This trial is currently completed. The enrollment target is 115 participants. The study started on 2011-01-03. Estimated completion is 2015-03-24.
What interventions are being tested in trial NCT01982591?
The interventions under investigation include: laboratory biomarker analysis (OTHER), questionnaire administration (OTHER).
Who is sponsoring clinical trial NCT01982591?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.